DUBLIN, March 9, 2018 /PRNewswire/ --
The "Global Molecular Diagnostics 2012-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.
The Global Molecular Diagnostics Partnering 2010-2018 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest Molecular Diagnostics agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals.
The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
One of the key highlights of the report is that over 660 online deal records of actual Molecular Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
Key benefits
- In-depth understanding of Molecular Diagnostics deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Molecular Diagnostics agreements with numerous real life case studies
- Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
- Identify most active Molecular Diagnostics dealmakers since 2010
- Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Molecular Diagnostics Partnering Terms and Agreements includes:
- Trends in Molecular Diagnostics dealmaking in the biopharma industry since 2010
- Analysis of Molecular Diagnostics deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Molecular Diagnostics deals
- Access to Molecular Diagnostics contract documents
- Leading Molecular Diagnostics deals by value since 2010
- Most active Molecular Diagnostics dealmakers since 2010
In Global Molecular Diagnostics Partnering 2010-2018: Deal trends, players, financials and forecasts, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Molecular Diagnostics dealmaking
2.1. Introduction
2.2. Molecular Diagnostics partnering over the years
2.3. Most active Molecular Diagnostics dealmakers
2.4. Molecular Diagnostics partnering by deal type
2.5. Molecular Diagnostics partnering by therapy area
2.6. Deal terms for Molecular Diagnostics partnering
2.6.1 Molecular Diagnostics partnering headline values
2.6.2 Molecular Diagnostics deal upfront payments7
2.6.3 Molecular Diagnostics deal milestone payments
2.6.4 Molecular Diagnostics royalty rates
Chapter 3 - Leading Molecular Diagnostics deals
3.1. Introduction
3.2. Top Molecular Diagnostics deals by value
Chapter 4 - Most active Molecular Diagnostics dealmakers
4.1. Introduction
4.2. Most active Molecular Diagnostics dealmakers
4.3. Most active Molecular Diagnostics partnering company profiles
Chapter 5 - Molecular Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Molecular Diagnostics contracts dealmaking directory
Chapter 6 - Molecular Diagnostics dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 - Molecular Diagnostics deals by company A-Z
Appendix 2 - Molecular Diagnostics deals by stage of development
For more information about this report visit https://www.researchandmarkets.com/research/8zmd83/global_molecular?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-molecular-diagnostics-2012-2018-access-to-over-660-deal-records-300611438.html
SOURCE Research and Markets
Share this article